Quanterix (QTRX)
(Delayed Data from NSDQ)
$15.36 USD
-0.11 (-0.71%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $15.35 -0.01 (-0.07%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.36 USD
-0.11 (-0.71%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $15.35 -0.01 (-0.07%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum F VGM
Zacks News
Boston Scientific (BSX) Expands Globally Amid FX Concerns
by Zacks Equity Research
Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.
CVS Health's (CVS) Cordavis to Focus on Biosimilar Products
by Zacks Equity Research
CVS Health's (CVS) wholly owned subsidiary, Cordavis, is set to bring high-quality biosimilar products to the market.
NanoString (NSTG) Advances in Xenotransplantation With New Study
by Zacks Equity Research
NanoString's (NSTG) nCounter Analysis System facilitates bulk tissue transcriptome profiling, revealing the intricacies of the immune response through the nCounter Human Organ Transplant Panel.
Myriad Genetics (MYGN) Teams Up to Assess Breast Cancer Risk
by Zacks Equity Research
Myriad Genetics (MYGN) announces collaboration with Onsite Women's Health to develop a breast cancer risk assessment program.
Align (ALGN) Rides on Growing Invisalign Sales, New Alliances
by Zacks Equity Research
Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions.
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD), backed by the continued demand for digital health solutions.
Teleflex (TFX) Upgrades the Arrow ErgoPack Complete System
by Zacks Equity Research
Teleflex's (TFX) expanded Arrow ErgoPack Complete Kit now includes Hemodialysis and Large Bore catheters.
Edwards Lifesciences (EW) Rides on TAVR Amid Rise in Costs
by Zacks Equity Research
Edwards Lifesciences' (EW) Surgical Structural Heart business growth is driven by increased penetration of its premium RESILIA products across all regions.
Illumina (ILMN) Expands Presence in India With New Facility
by Zacks Equity Research
Illumina (ILMN) boosts genomic capabilities in India with a new state-of-the-art Solutions Center.
Quanterix Corporation (QTRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 55.56% and 18.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Quanterix (QTRX) Advances in Alzheimer's Diagnosis With LucentAD
by Zacks Equity Research
Quanterix (QTRX) LucentAD biomarker blood test aims to assist healthcare providers in evaluating patients who show cognitive symptoms consistent with the early signs of AD.
Quanterix Corporation (QTRX) Surges 13.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 55.56% and 11.77%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Quanterix Corporation (QTRX) Soars 33.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Quanterix Corporation (QTRX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 5.66% and 1.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
PetIQ (PETQ) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
PetIQ (PETQ) delivered earnings and revenue surprises of 37.50% and 4.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 129.17% and 11.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Medtronic (MDT) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 3.17% and 2.76%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Quanterix Corporation (QTRX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 4.76% and 18.11%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CytoSorbents (CTSO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
CytoSorbents (CTSO) delivered earnings and revenue surprises of -75% and 9.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 8.33% and 0.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict a 73% Upside in Quanterix Corporation (QTRX): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 73.2% in Quanterix Corporation (QTRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Quanterix Corporation (QTRX) Loses 53.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Quanterix Corporation (QTRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Quanterix Corporation (QTRX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 0% and 20.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
BellRing Brands (BRBR) Beats Q3 Earnings Estimates
by Zacks Equity Research
BellRing Brands (BRBR) delivered earnings and revenue surprises of 3.33% and 4.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?